Key result
Saxagliptin linked to ~27% higher risk of heart failure hospitalization vs. placebo in diabetes.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Eberhard Standl (2014) conducted a letter in Diabetes Mellitus. Saxagliptin vs. Placebo was evaluated on Hospitalization for heart failure. Saxagliptin was associated with a 27% increase in hospitalization for heart failure compared with placebo among patients with diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: